More recently, a SARS-CoV-2 vaccine that contains a TLR7/8 agonist, Covaxin, was approved for emergency use by the WHO for the prevention of COVID-19 with an overall estimated efficacy in preventing COVID-19 of 77.8%49, demonstrating the safety and efficacy of TLR7/8 agonists as vaccine adjuvants in a human population. The gene discussed is TLR7; the disease is COVID-19.